# Tirzepatide Research: Mechanism, Trials, and the 2024-2025 Evidence > Tirzepatide research from discovery through the 2025 head-to-head SURMOUNT-5 trial. The dual GIP/GLP-1 mechanism, the SURPASS and SURMOUNT programmes, and the emerging evidence on MASH, sleep apnea, and heart failure. ## The short version Tirzepatide is a 39-amino-acid synthetic peptide that was engineered to activate two gut-hormone receptors simultaneously — the GIP receptor and the GLP-1 receptor. It is the first drug of its class to do this in a single molecule, and the clinical trial record across more than ten large randomised controlled trials in humans shows it produces larger reductions in blood sugar and body weight than the prior generation of selective GLP-1 agonists. The foundational 2025 head-to-head study (SURMOUNT-5) measured a 6.5-percentage-point greater body weight reduction with tirzepatide versus the comparator at 72 weeks [5]. The SURPASS programme across type 2 diabetes established superiority or non-inferiority versus multiple glucose-lowering agents. The page below walks through the mechanism, the trial data, and the recent 2024-2025 studies that are sharpening the picture on body composition, physical function, and cardiovascular outcomes. ## What is tirzepatide: a dual incretin peptide Tirzepatide's scientific name at development was LY3298176. Its structure: a 39-amino-acid backbone based on the native GIP sequence, modified with a C20 fatty diacid moiety attached through a glutamic acid linker, giving the molecule high albumin affinity and an approximately five-day elimination half-life in humans — long enough to support once-weekly subcutaneous dosing [1]. The fatty-diacid arm is the engineering that distinguishes it from native GIP and GLP-1, both of which are rapidly degraded in circulation. Molecular formula C225H348N48O68, molecular weight 4813.53 Da, CAS number 2023788-19-2, ATC code A10BX16. In vitro receptor-occupancy and signalling assays showed tirzepatide is an imbalanced dual agonist, engaging the GIP receptor (GIPR) to a greater degree than the GLP-1 receptor (GLP-1R), and exhibiting biased GLP-1R signalling that favours cyclic AMP (cAMP) generation over beta-arrestin recruitment [2]. Beta-arrestin limits the insulin response to GLP-1 but not to GIP or tirzepatide — the biased profile is proposed to translate into a more sustained insulin-secretion response. Cryo-EM structural work later visualised tirzepatide bound to both receptors at near-atomic resolution, revealing how a single molecule can simultaneously engage two distinct receptor architectures [17]. A 2025 narrative review updated the mechanistic picture of tirzepatide's dual-agonist receptor pharmacology [26]. The tirzepatide peptide acts on the gut-brain axis through both receptors: GLP-1R agonism slows gastric emptying, suppresses glucagon, and acts on central appetite circuits; GIPR agonism in the brain and in adipose tissue adds complementary energy-expenditure and satiety signals. A 2025 Annual Review article synthesised how combining brain-GIP-receptor and hepatic/adipose glucagon-receptor activation with GLP-1R agonism curbs feeding and increases caloric combustion [27]. ## Tirzepatide vs semaglutide: the head-to-head evidence The most-searched comparison in the tirzepatide literature is tirzepatide vs semaglutide — both are once-weekly subcutaneous injectables, both are FDA-approved for type 2 diabetes and chronic weight management, and for most patients they are the two most relevant comparisons. **SURPASS-2** (Frias JP et al., N Engl J Med 2021, n=1879): a 40-week open-label phase 3 trial in adults with type 2 diabetes. Tirzepatide at all three doses (5, 10, and 15 mg once weekly) reduced glycated haemoglobin (HbA1c — a blood marker reflecting average blood sugar over roughly three months) by 2.01, 2.24, and 2.30 percentage points, versus 1.86 percentage points with the comparator (1 mg once weekly). Tirzepatide was non-inferior and superior at all three doses. Body-weight reductions were greater with tirzepatide: treatment differences of -1.9, -3.6, and -5.5 kg across doses [3]. **SURMOUNT-5** (Aronne LJ et al., N Engl J Med 2025, n=751): the first direct head-to-head randomised trial in adults with obesity but without type 2 diabetes, randomising participants to the maximum tolerated dose of tirzepatide (10 or 15 mg) or the maximum tolerated dose of the comparator (1.7 or 2.4 mg once weekly) for 72 weeks. The primary result: mean body weight change at 72 weeks was -20.2% with tirzepatide versus -13.7% with the comparator (P<0.001). Higher proportions of tirzepatide participants reached >=10%, >=15%, >=20%, and >=25% weight reduction thresholds. Waist circumference reductions were also greater with tirzepatide [5]. An indirect comparison using multilevel network meta-regression (ML-NMR) adjusting for sex, ethnicity, and baseline differences also found tirzepatide 10 mg and 15 mg produced greater weight reduction than an oral formulation of the comparator (50 mg oral): mean weight differences of -4.48% (10 mg) and -5.59% (15 mg), with greater reductions in waist circumference and higher odds of achieving 5%, 10%, 15%, and 20% weight reduction [29]. ## The SURMOUNT programme: weight management in obesity **SURMOUNT-1** (Jastreboff AM et al., N Engl J Med 2022, n=2539): the landmark 72-week phase 3 RCT in adults with obesity (BMI >=30, or >=27 with a weight-related complication) and without type 2 diabetes. Mean body weight change at 72 weeks: -15.0% at 5 mg, -19.5% at 10 mg, and -20.9% at 15 mg, versus -3.1% with placebo. Gastrointestinal events were the most common adverse effects, occurring primarily during dose escalation [4]. A 2025 extended follow-up from the SURMOUNT-1 programme (Jastreboff AM et al., N Engl J Med 2025) also assessed tirzepatide's effects on diabetes prevention in adults with obesity and prediabetes over extended follow-up, finding sustained weight reduction and reduced progression to type 2 diabetes [28]. **SURMOUNT-3** (Wadden TA et al., Nat Med 2023): after a 12-week intensive lifestyle intervention achieving at least 5% weight reduction, participants randomised to tirzepatide achieved an additional mean weight change of -18.4% from randomisation versus +2.5% with placebo over 72 weeks — a combinatorial benefit demonstrating efficacy even on top of prior behavioural weight loss [30]. **Body composition: the DXA substudy.** A SURMOUNT-1 DXA substudy (Look M et al., Diabetes Obes Metab 2025, n=160) used dual-energy X-ray absorptiometry to separate fat mass from lean mass. Of weight lost, approximately 75% was fat mass and approximately 25% was lean mass, a proportion consistent across most subgroup analyses [10]. A broader systematic review estimated the median muscle-attributable share of weight loss near 28% across incretin trials [15]. ## Beyond glycaemia: new approved and emerging indications The recent-research-2024-2025 lens also covers trials that extended tirzepatide's evidence base into non-diabetes conditions. **Obstructive sleep apnea (OSA).** In SURMOUNT-OSA (Malhotra A et al., N Engl J Med 2024, two cohorts): in adults with obesity and moderate-to-severe OSA, tirzepatide reduced the apnea-hypopnea index (AHI — the number of breathing interruptions per hour of sleep) by 25.3 events per hour in participants not using a PAP device and by 29.3 events per hour in PAP users, versus approximately 5 events per hour with placebo over 52 weeks. FDA-approved for this indication [24]. **Metabolic dysfunction-associated steatohepatitis (MASH).** In SYNERGY-NASH (Loomba R et al., N Engl J Med 2024, NCT04166773): in adults with MASH — a progressive fatty liver disease, formerly called NASH, characterised by liver inflammation and fibrosis — tirzepatide led to MASH resolution without worsening of fibrosis more often than placebo [25]. **Heart failure with preserved ejection fraction (HFpEF) and obesity.** In SUMMIT (Packer M et al., N Engl J Med 2025, NCT04847557): in patients with HFpEF — a form of heart failure in which the heart's pumping fraction remains normal — and obesity, tirzepatide improved heart-failure outcomes and reduced events versus placebo [23]. A 2025 systematic review and network meta-analysis in Nature Medicine (McGowan B et al., 56 RCTs, 60,307 patients) confirmed both semaglutide and tirzepatide achieved greater than 10% total body weight loss versus placebo, and that tirzepatide was additionally effective for remission of OSA and MASH [11]. **Physical function.** A 2026 systematic review and meta-analysis (Schmidt PHS et al., Diabetes Obes Metab 2026) found improvements in physical function with tirzepatide as measured by SF-36 (mean difference 2.26 points, 95% CI 1.76–2.76) and IWQOL-Lite-CT (mean difference 10.10 points, 95% CI 8.61–11.60), with benefits consistent at both 10 and 15 mg, though extremely high between-study heterogeneity (I2 = 99.8%) limits interpretation of the pooled estimates [31]. **Cardiovascular outcomes.** SURPASS-CVOT (Nicholls SJ et al., N Engl J Med 2025, NCT04255433) compared tirzepatide with an established comparator in adults with type 2 diabetes and atherosclerotic cardiovascular disease, providing the cardiovascular-safety readout for the SURPASS programme [32]. --- Peer-reviewed trial findings on tirzepatide, walked through step by step — not a prescription, not a clinic, not a vendor.